Adaptive Biotechnologies Corp (NASDAQ:ADPT) has a beta value of 1.44 and has seen 1.16 million shares traded in the last trading session. The company, currently valued at $851.03M, closed the last trade at $5.26 per share which meant it lost -$0.05 on the day or -0.94% during that session. The ADPT stock price is -10.27% off its 52-week high price of $5.80 and 56.65% above the 52-week low of $2.28. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.84 million shares traded. The 3-month trading volume is 1.09 million shares.
The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is Hold stock at the moment, with a recommendation rating of 1.50. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 11 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.29.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information
Sporting -0.94% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ADPT stock price touched $5.26 or saw a rise of 4.88%. Year-to-date, Adaptive Biotechnologies Corp shares have moved 7.35%, while the 5-day performance has seen it change 12.63%. Over the past 30 days, the shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) have changed -4.71%. Short interest in the company has seen 9.48 million shares shorted with days to cover at 8.21.
Wall Street analysts have a consensus price target for the stock at $14, which means that the shares’ value could jump 62.43% from current levels. The projected low price target is $5.0 while the price target rests at a high of $18.0. In that case, then, we find that the current price level is -242.21% off the targeted high while a plunge would see the stock lose 4.94% from current levels.
Adaptive Biotechnologies Corp (ADPT) estimates and forecasts
Figures show that Adaptive Biotechnologies Corp shares have underperformed across the wider relevant industry. The company’s shares have gained 63.35% over the past 6 months, with this year growth rate of 10.87%, compared to 17.50% for the industry. Revenue growth from the last financial year stood is estimated to be 1.10%.
7 analysts offering their estimates for the company have set an average revenue estimate of 40.21M for the current quarter. 7 have an estimated revenue figure of 46.57M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -32.91% over the past 5 years. Earnings growth for 2024 is a modest 22.02% while over the next 5 years, the company’s earnings are expected to increase by 21.60%.
ADPT Dividends
Adaptive Biotechnologies Corp is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders
Insiders own 1.93% of the company shares, while shares held by institutions stand at 98.77% with a share float percentage of 100.71%. Investors are also buoyed by the number of investors in a company, with Adaptive Biotechnologies Corp having a total of 239.0 institutions that hold shares in the company. The top two institutional holders are VIKING GLOBAL INVESTORS LP with over 29.99 million shares worth more than $108.58 million. As of 2024-06-30, VIKING GLOBAL INVESTORS LP held 20.5736% of shares outstanding.
The other major institutional holder is RUBRIC CAPITAL MANAGEMENT LP, with the holding of over 14.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $50.68 million and represent 9.603% of shares outstanding.
